ProQR Therapeutics NV
(NASDAQ : PRQR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.18%177.200.7%$1337.98m
MRKMerck & Co., Inc. -0.26%90.930.7%$1164.75m
PFEPfizer Inc. -1.28%51.760.9%$1099.46m
LLYEli Lilly & Co. -1.23%320.241.1%$1032.80m
BMYBristol-Myers Squibb Co. -1.08%76.171.0%$997.00m
ABBVAbbVie, Inc. -0.59%152.261.9%$953.09m
AZNAstraZeneca Plc -1.26%65.241.0%$435.93m
SGENSeagen Inc. 1.39%179.405.7%$320.28m
TPTXTurning Point Therapeutics, Inc. -0.09%75.190.0%$287.85m
GSKGSK Plc -0.35%43.380.2%$275.50m
NVSNovartis AG -1.05%83.640.2%$162.84m
HZNPHorizon Therapeutics Plc 0.44%80.115.4%$162.52m
MRTXMirati Therapeutics, Inc. 5.38%70.741.6%$154.60m
ALNYAlnylam Pharmaceuticals, Inc. 1.68%148.308.1%$142.88m
NVONovo Nordisk A/S -0.78%110.560.1%$142.10m

Company Profile

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.